Johnson & Johnson (J&J) has reported new findings from the QUASAR long-term extension study of Tremfya (guselkumab) for ...
China's Corxel Pharmaceuticals' latest round is further evidence of biotech investors' insatiable appetite for companies with obesity programmes, with backers ploughing $287 million into its Series D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results